Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Receivables (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Receivables data on record, last reported at $523000.0 in Q3 2025.

  • For Q3 2025, Receivables fell 97.45% year-over-year to $523000.0; the TTM value through Sep 2025 reached $523000.0, down 97.45%, while the annual FY2024 figure was $4.6 million, 255.03% up from the prior year.
  • Receivables reached $523000.0 in Q3 2025 per SGMO's latest filing, up from $372000.0 in the prior quarter.
  • Across five years, Receivables topped out at $20.5 million in Q3 2024 and bottomed at $366000.0 in Q1 2025.
  • Average Receivables over 5 years is $5.1 million, with a median of $4.6 million recorded in 2024.
  • Peak YoY movement for Receivables: soared 1071.2% in 2024, then crashed 97.45% in 2025.
  • A 5-year view of Receivables shows it stood at $6.4 million in 2021, then fell by 29.36% to $4.5 million in 2022, then plummeted by 71.01% to $1.3 million in 2023, then skyrocketed by 255.03% to $4.6 million in 2024, then plummeted by 88.69% to $523000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $523000.0 in Q3 2025, $372000.0 in Q2 2025, and $366000.0 in Q1 2025.